Clinical, virological and immunological aspects of adoptive cell therapy against EBV-related diseases


Submitted: 17 February 2014
Accepted: 17 February 2014
Published: 30 September 2009
Abstract Views: 747
PDF: 1366
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

From an immunological point of view, tumors with a viral etiology have an important advantage, as their associated antigens are not self and, thereby, are strongly immunogenic.This is well demonstrated in the case of EBVassociated tumors, which represent one of the main target of adoptive immunotherapy. Here, we describe the results of trials conducted thus far with EBV-specific cytotoxic T lymphocytes, in terms of clinical, virological and immunological responses, underlining the relevance of the continuous interplay between oncologists, clinical microbiologists and immunologists for an effective management of these disorders.

Merlo, A., Turrini, R., Comoli, P., Dolcetti, R., & Rosato, A. (2009). Clinical, virological and immunological aspects of adoptive cell therapy against EBV-related diseases. Microbiologia Medica, 24(3). https://doi.org/10.4081/mm.2009.2523

Downloads

Download data is not yet available.

Citations